IndranilBhattacharyaDO

PubMed

• Approval of Drugs With Unmet Trial End Points.
  Indranil Bhattacharya, Iraj Daizadeh, Andrew S Robertson> ;JAMA Internal Medicine. 2023 Aug 1
• Think Rare, Think Inside and Out: Simple Question-Based Approach to Complex Rare Disease Drug Development.
  Indranil Bhattacharya, Mariam A Ahmed> ;Journal of Clinical Pharmacology. 2022 Dec 1
• 14 citations
  Current and Next Steps Toward Prediction of Human Dose for Gene Therapy Using Translational Dose-Response Studies
  Sergey Aksenov, John Roberts, Ganesh Mugundu, Karen Thudium Mueller, Indranil Bhattacharya, Michael A. Tortorici> ;Clinical Pharmacology and Therapeutics. 2021 Nov 1
• 14 citations
  A Dynamic Quantitative Systems Pharmacology Model of Inflammatory Bowel Disease: Part 1 - Model Framework.
  Katharine V. Rogers, Steven W. Martin, Indranil Bhattacharya, Ravi Shankar P. Singh, Satyaprakash Nayak> ;Clinical and Translational Science. 2021 Jan 1
• 7 citations
  A Dynamic Quantitative Systems Pharmacology Model of Inflammatory Bowel Disease: Part 2 - Application to Current Therapies in Crohn's Disease.
  Katharine V. Rogers, Steven W. Martin, Indranil Bhattacharya, Ravi Shankar P. Singh, Satyaprakash Nayak> ;Clinical and Translational Science. 2021 Jan 1
• 12 citations
  First-in-human, randomized dose-escalation study of the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of PF-06480605 in healthy subjects.
  Christopher Banfield, Dan Rudin, Indranil Bhattacharya, Kosalaram Goteti, Gang Li, Mina Hassan-Zahraee, Lisa S. Brown, Kenneth E. Hung, Sylvester Pawlak, Christopher L...> ;British Journal of Clinical Pharmacology. 2020 Jan 28
• 1 citations
  End Points, Collection, Processing, and Time: Four Key Elements to Consider When Planning for Use of Handheld Devices in a Drug Development Setting
  Vivek Pradhan, Anne C. Heatherington, Indranil Bhattacharya> ;Clinical Pharmacology and Therapeutics. 2020 Jan 16
• 2 citations
  Comparing Model Performance in Characterizing the PK/PD of the Anti-Myostatin Antibody Domagrozumab
  Abhinav Tiwari, Indranil Bhattacharya, Phylinda L. S. Chan, Lutz Harnisch> ;Clinical and Translational Science. 2020 Jan 1
• 39 citations
  Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Domagrozumab (PF-06252616), an Antimyostatin Monoclonal Antibody, in Healthy Subjects
  Indranil Bhattacharya, Sylvester Pawlak, Shannon Marraffino, Jared Christensen, Sarah P. Sherlock, Christine Alvey, Carl Morris, Steven Arkin, Michael Binks> ;Clinical Pharmacology in Drug Development. 2018 Jun 1
• 18 citations
  Application of Quantitative Pharmacology Approaches in Bridging Pharmacokinetics and Pharmacodynamics of Domagrozumab From Adult Healthy Subjects to Pediatric Patients...
  Indranil Bhattacharya, Zorayr Manukyan, Phylinda L. S. Chan, Anne C. Heatherington, Lutz Harnisch> ;Journal of Clinical Pharmacology. 2018 Mar 1
• 6 citations
  Know Your Variability: Challenges in Mechanistic Modeling of Inflammatory Response in Inflammatory Bowel Disease (IBD).
  Katharine V. Rogers, Indranil Bhattacharya, Steven W. Martin, Satyaprakash Nayak> ;Clinical and Translational Science. 2018 Jan 1
• 5 citations
  Safety and Efficacy of SBI-087, a Subcutaneous Agent for B Cell Depletion, in Patients with Active Rheumatoid Arthritis: Results from a Phase II Randomized, Double-bli...
  Nemanja Damjanov, Małgorzata Tłustochowicz, Jacob A. Aelion, Maria Greenwald, Annette Diehl, Indranil Bhattacharya, Elena Peeva, Sandeep Menon, Ian Gourley> ;The Journal of Rheumatology. 2016 Dec 1
• 3 citations
  Applying the best of oncology drug development paradigms to the non-malignant space.
  Indranil Bhattacharya, Anne C. Heatherington, Jeremy Barton> ;Drug Discovery Today. 2016 Dec 1
• 8 citations
  Assessing the Impact of Tissue Target Concentration Data on Uncertainty in In Vivo Target Coverage Predictions.
  Abhinav Tiwari, H Luo, Xiaoying Chen, Pratap Singh, Indranil Bhattacharya, P Jasper, JE Tolsma, Hannah M. Jones, Anup Zutshi, Anson K. Abraham> ;CPT. 2016 Oct 1
• 8 citations
  Making Every Subject Count: A Case Study of Drug Development Path for Medication in a Pediatric Rare Disease.
  Indranil Bhattacharya, Zorayr Manukyan, Phylinda L. S. Chan, Lutz Harnisch, Anne C. Heatherington> ;Clinical Pharmacology and Therapeutics. 2016 Oct 1
• 22 citations
  Translational Pharmacokinetic/Pharmacodynamic Analysis of MYO-029 Antibody for Muscular Dystrophy.
  Pratap Singh, H Rong, T Gordi, J Bosley, Indranil Bhattacharya> ;Clinical and Translational Science. 2016 Oct 4
• 2 citations
  Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of SBI-087, a CD20-Directed B-cell Depleting Agent: Phase 1 Dose Escalating Studies in Patients Wi...
  Stanley Cohen, Megan E.B. Clowse, Patricia Pardo, Indranil Bhattacharya, Sandeep Menon, Ian Gourley, Annette Diehl> ;Clinical Therapeutics. 2016 Jun 1
• 15 citations
  Safety, Pharmacokinetic, and Pharmacodynamic Evaluation After Single and Multiple Ascending Doses of a Novel Selective Androgen Receptor Modulator in Healthy Subjects.
  Indranil Bhattacharya, Sanela Tarabar, Yali Liang, Vivek Pradhan, Jane Owens, Barry Oemar> ;Clinical Therapeutics. 2016 Jun 1
• 11 citations
  Reassessment of tigecycline bone concentrations in volunteers undergoing elective orthopedic procedures
  Indranil Bhattacharya, Mark H. Gotfried, Allena J. Ji, James P. Saunders, Ian Gourley, Annette Diehl, Joan M. Korth-Bradley> ;Journal of Clinical Pharmacology. 2014 Jan 1
• 3 citations
  Repeat-dose sirolimus pharmacokinetics and pharmacodynamics in patients with hepatic allografts.
  Jürg Reichen, Felix Stickel, Indranil Bhattacharya, Kyle Matschke, E Maller, Joan M. Korth-Bradley> ;European Journal of Clinical Pharmacology. 2012 May 1
• Comparative Sirolimus Pharmacokinetics After Single-Dose Administration of Two Prototype 0.5-mg Tablets in Healthy Volunteers
  Joan M. Korth-Bradley, Indranil Bhattacharya, Kyle Matschke, Annette Diehl, Carl Longfellow, Ian Gourley> ;Clinical Pharmacology in Drug Development. 2012 Apr 1
• Join now to see all